Ameriflex Group Inc. Buys 1,452 Shares of Amgen Inc. $AMGN

Ameriflex Group Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 367.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,847 shares of the medical research company’s stock after acquiring an additional 1,452 shares during the quarter. Ameriflex Group Inc.’s holdings in Amgen were worth $521,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Sequoia Financial Advisors LLC boosted its holdings in Amgen by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after purchasing an additional 3,619 shares during the last quarter. Atlantic Union Bankshares Corp increased its stake in Amgen by 165.0% in the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock valued at $2,972,000 after buying an additional 6,627 shares during the last quarter. Davis Capital Management acquired a new stake in Amgen in the 3rd quarter valued at $1,841,000. D.A. Davidson & CO. lifted its position in Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after buying an additional 6,222 shares in the last quarter. Finally, Global Wealth Management Investment Advisory Inc. boosted its stake in shares of Amgen by 56.2% during the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after buying an additional 4,699 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on AMGN. TD Cowen restated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Mizuho increased their price target on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft raised their price target on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research note on Thursday, February 5th. Freedom Capital lowered Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Finally, Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $354.17.

Amgen Trading Up 0.5%

AMGN stock opened at $369.53 on Friday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a market capitalization of $199.20 billion, a PE ratio of 25.97, a price-to-earnings-growth ratio of 3.65 and a beta of 0.45. The company’s 50-day simple moving average is $353.26 and its 200 day simple moving average is $322.43. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the previous year, the company earned $5.31 EPS. The business’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s payout ratio is currently 70.84%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY‑2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex‑dividend May 15), reinforcing shareholder returns and supporting income‑oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare‑disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short‑interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late‑stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.